Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Sep;78(3):525-31.
doi: 10.1007/s00280-016-3106-7. Epub 2016 Jul 15.

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

Kan Yonemori  1 , Kenji Tamura  2 , Makoto Kodaira  2 , Koshi Fujikawa  3 , Tamotsu Sagawa  3 , Taito Esaki  4 , Tsuyoshi Shirakawa  4 , Fumihiko Hirai  5 , Yuki Yokoi  6 , Toshio Kawata  6 , Ben Hatano  6 , Yasuo Takahashi  3
Affiliations
Clinical Trial

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

Kan Yonemori et al. Cancer Chemother Pharmacol. 2016 Sep.

Abstract

Purpose: This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid tumours. The pharmacokinetic profile and antitumour activity of olaparib tablets were also assessed.

Methods: In this open-label, multicentre study (D081BC00001; NCT01813474), a single dose of olaparib (200 or 300 mg, tablets) was administered on day 1, followed 48 h afterwards by multiple dosing (200 or 300 mg twice daily [bid]) for 28-day cycles. Doses were escalated in successive cohorts, with an expansion cohort enrolled at the highest dose that was confirmed to be tolerable during dose escalation.

Results: Twenty-eight patients were enrolled and 23 were treated (n = 4, 7 and 12 at 200, 300 and 300 [expansion] mg bid, respectively). No patients experienced a dose-limiting toxicity, so the maximum tolerated dose was not defined. The most frequent adverse events were nausea (43.5 %), decreased appetite (30.4 %), anaemia (26.1 %) and constipation (26.1 %). No patient had dose reductions, two had dose interruptions, and two discontinued treatment because of adverse events. Absorption of olaparib was rapid following single and multiple dosing, and plasma concentrations declined biphasically after single dosing. No patients had a confirmed antitumour response.

Conclusions: Olaparib tablet doses of 200 and 300 mg bid were considered tolerable in Japanese patients with advanced solid tumours. Consistent with the global olaparib programme, 300 mg bid was selected as the recommended tablet dose for future studies.

Clinical trial registration number: NCT01813474.

Keywords: Clinical trial, Phase I; Olaparib; Poly(ADP-ribose) polymerase inhibitors; Safety; Solid tumours.

PubMed Disclaimer

Conflict of interest statement

Kan Yonemori reports grants from AstraZeneca during the conduct of the study and personal fees from Eisai Co., Ltd, outside the submitted work. Kenji Tamura, Makoto Kodaira, Koshi Fujikawa, and Tamotsu Sagawa report personal fees from AstraZeneca during the conduct of the study. Taito Esaki reports grants from AstraZeneca during the conduct of the study, and outside of the submitted work: grants and personal fees from Boehringer Ingelheim, Eli Lilly, Merck Serono, and Taiho Pharmaceutical Co. Ltd; grants from Astellas, AstraZeneca, Bayer, Daiichi Sankyo, MSD, Novartis Pharma, Ono Pharmaceutical Co. Ltd, Sanofi, and Sumitomo Dainippon; and personal fees from Chugai and Yakult. Tsuyoshi Shirakawa reports personal fees from AstraZeneca during the conduct of the study. Fumihiko Hirai reports grants from AstraZeneca during the conduct of the study, and outside of the submitted work: grants and personal fees from Novartis Pharma; personal fees from Chugai Pharmaceutical Co., Ltd, Eli Lilly, Kyowa Hakko Kirin Co., Ltd, Ono Pharmaceutical Co., Ltd, and Taiho Pharmaceutical Co., Ltd. Yuki Yokoi, Toshio Kawata, Ben Hatano and Yasuo Takahashi report personal fees from AstraZeneca during the conduct of the study.

Figures

Fig. 1
Fig. 1
Phase I study design with dose-escalation and dose-expansion phases
Fig. 2
Fig. 2
Plasma concentrations of olaparib following a single and b multiple dosing. SD standard deviation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–5599. doi: 10.1158/0008-5472.CAN-12-2753. - DOI - PMC - PubMed
    1. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O’Connor MJ, Jonkers J. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008;14:3916–3925. doi: 10.1158/1078-0432.CCR-07-4953. - DOI - PubMed
    1. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O’Connor MJ, Martin NM, Borst P, Jonkers J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA. 2008;105:17079–17084. doi: 10.1073/pnas.0806092105. - DOI - PMC - PubMed
    1. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–134. doi: 10.1056/NEJMoa0900212. - DOI - PubMed
    1. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245–251. doi: 10.1016/S0140-6736(10)60893-8. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources